pp-009 Tablets 150 mg
Dossier type
CTD
Dossier status
Ready to file
Country of origin
China
GMP approvals
China
Comments
CDK4/6 inhibitor. Marketed for HER2 negative breast cancer; Phase 2 - Breast cancer; HER2 positive breast cancer; Phase 1/2 Malignant melanoma
Manufacturer #17216
Global developer of innovative drugs in oncology, metabolic, autoimmune, and cardiovascular diseases, with 14 in-house products and multiple partnerships. Over 5,000 R&D staff across global centers and strong IP, clinical pipeline, and high-standard manufacturing.
Manufacturer usually replies in 41 days